These results suggest that regulating NLRP3 inflammasome activation with small molecule inhibitors is a potential therapeutic strategy to treat or prevent the pathological outcomes of NAFLD. This evidence concerns the gene NLRP3 and metabolic dysfunction-associated steatotic liver disease.